Skip to main content

CSPC Starts China Trial of Lymphoma Treatment

CSPC Pharma has begun a China bridging trial of Copiktra® (duvelisib) in patients with relapsed or refractory follicular lymphoma. Copiktra is an oral inhibitor of phosphoinositide 3-kinase (PI3K). It was approved in 2018 in the US to treat adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Copiktra is the first approved dual inhibitor of PI3K-delta and PI3K-gamma in the US. CSPC, a Shijiazhuang, Hebei Province company that makes novel and generic drugs, in-licensed China rights to Copiktra from Boston's Verastem in 2018. More details.... Stock Symbol: (HK: 1093) (NSDQ: VSTM) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.